Awarded to Taro Pharmaceuticals Industries, this generic approval is targeted to reduce the risk of major cardiovascular events in adult patients with coronary artery disease and the risk of major thrombotic vascular events in adult patients with peripheral artery disease, including patients who have recently undergone a lower extremity revascularization procedure.